Clinical Trial Update: Gemcitabine/Irinotecan/ZD1839 vs Paclitaxel/Carboplatin/Etoposide/ZD1839 in Carcinoma of Unknown Primary Site [Phase 3]

View source ↗

Summary

Phase 3 randomized trial evaluating gemcitabine/irinotecan/Gefitinib versus paclitaxel/carboplatin/etoposide/Gefitinib in carcinoma of unknown primary; the stud…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Carcinoma of Unknown Primary

Drugs mentioned

• Camptosar (irinotecan)
• Gemzar (gemcitabine)
• Iressa (gefitinib)
• Paraplatin (Carboplatin)
• Taxol (paclitaxel)
• VePesid (etoposide)

Snippet

Sponsor: SCRI Development Innovations, LLC | Conditions: Neoplasms, Unknown Primary | Phase 3 | Status: COMPLETED | Results posted: 2013-05-03